Cranial and intra-axial metastasis originating from a primary ovarian Dysgerminoma
Dysgerminomas are aggressive germ cell tumors that typically have a favorable prognosis, especially in patients diagnosed with early stage disease. We recount the history of a 23-year-old woman who was treated for a stage IA ovarian dysgerminoma in November 2017. Postoperatively, the patient was non...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-08-01
|
Series: | Gynecologic Oncology Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235257891930061X |
id |
doaj-58620e66db5d4212a45e64eacf3046bf |
---|---|
record_format |
Article |
spelling |
doaj-58620e66db5d4212a45e64eacf3046bf2020-11-24T21:29:49ZengElsevierGynecologic Oncology Reports2352-57892019-08-01295557Cranial and intra-axial metastasis originating from a primary ovarian DysgerminomaTiffany L. Beck0Hitomi Momose1Jeffrey M. Dym2Vikas Y. Rao3Randy Bohart4Bram H. Goldstein5Gynecologic Oncology Associates, Newport Beach, CA, United States of AmericaSt. Joseph Health, Department of Pathology, Mission Viejo, CA, United States of AmericaSt. Joseph Health, Department of Radiology, Mission Viejo, CA, United States of AmericaSt. Joseph Health, Department of Neurosurgery, Mission Viejo, CA, United States of AmericaOso Home Care, 17175 Gillette Avenue, Irvine, CA 92614, United States of AmericaOso Home Care, 17175 Gillette Avenue, Irvine, CA 92614, United States of America; Corresponding author at: Women's Cancer Research Foundation, 351 Hospital Road, Suite #506, Newport Beach, CA 92663, United States of America.Dysgerminomas are aggressive germ cell tumors that typically have a favorable prognosis, especially in patients diagnosed with early stage disease. We recount the history of a 23-year-old woman who was treated for a stage IA ovarian dysgerminoma in November 2017. Postoperatively, the patient was noncompliant insofar as obtaining routine lab evaluations; ten months later, she was diagnosed with a cranial metastasis that extended into the meninges. The patient subsequently underwent a craniotomy and adjuvant etoposide, bleomycin and cisplatin chemotherapy to which she initially responded; however, during cycle 4, she developed pancytopenia whereupon the chemotherapy was summarily discontinued. Thereafter, the patient was surveilled and currently, she remains in clinical remission. Early stage ovarian dysgerminoma, albeit rarely, has the capacity to metastasize to the cranium or brain, further underscoring the significance of employing active follow-up with these patients. Keywords: Ovarian dysgerminoma, Cranial metastasis, Treatmenthttp://www.sciencedirect.com/science/article/pii/S235257891930061X |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tiffany L. Beck Hitomi Momose Jeffrey M. Dym Vikas Y. Rao Randy Bohart Bram H. Goldstein |
spellingShingle |
Tiffany L. Beck Hitomi Momose Jeffrey M. Dym Vikas Y. Rao Randy Bohart Bram H. Goldstein Cranial and intra-axial metastasis originating from a primary ovarian Dysgerminoma Gynecologic Oncology Reports |
author_facet |
Tiffany L. Beck Hitomi Momose Jeffrey M. Dym Vikas Y. Rao Randy Bohart Bram H. Goldstein |
author_sort |
Tiffany L. Beck |
title |
Cranial and intra-axial metastasis originating from a primary ovarian Dysgerminoma |
title_short |
Cranial and intra-axial metastasis originating from a primary ovarian Dysgerminoma |
title_full |
Cranial and intra-axial metastasis originating from a primary ovarian Dysgerminoma |
title_fullStr |
Cranial and intra-axial metastasis originating from a primary ovarian Dysgerminoma |
title_full_unstemmed |
Cranial and intra-axial metastasis originating from a primary ovarian Dysgerminoma |
title_sort |
cranial and intra-axial metastasis originating from a primary ovarian dysgerminoma |
publisher |
Elsevier |
series |
Gynecologic Oncology Reports |
issn |
2352-5789 |
publishDate |
2019-08-01 |
description |
Dysgerminomas are aggressive germ cell tumors that typically have a favorable prognosis, especially in patients diagnosed with early stage disease. We recount the history of a 23-year-old woman who was treated for a stage IA ovarian dysgerminoma in November 2017. Postoperatively, the patient was noncompliant insofar as obtaining routine lab evaluations; ten months later, she was diagnosed with a cranial metastasis that extended into the meninges. The patient subsequently underwent a craniotomy and adjuvant etoposide, bleomycin and cisplatin chemotherapy to which she initially responded; however, during cycle 4, she developed pancytopenia whereupon the chemotherapy was summarily discontinued. Thereafter, the patient was surveilled and currently, she remains in clinical remission. Early stage ovarian dysgerminoma, albeit rarely, has the capacity to metastasize to the cranium or brain, further underscoring the significance of employing active follow-up with these patients. Keywords: Ovarian dysgerminoma, Cranial metastasis, Treatment |
url |
http://www.sciencedirect.com/science/article/pii/S235257891930061X |
work_keys_str_mv |
AT tiffanylbeck cranialandintraaxialmetastasisoriginatingfromaprimaryovariandysgerminoma AT hitomimomose cranialandintraaxialmetastasisoriginatingfromaprimaryovariandysgerminoma AT jeffreymdym cranialandintraaxialmetastasisoriginatingfromaprimaryovariandysgerminoma AT vikasyrao cranialandintraaxialmetastasisoriginatingfromaprimaryovariandysgerminoma AT randybohart cranialandintraaxialmetastasisoriginatingfromaprimaryovariandysgerminoma AT bramhgoldstein cranialandintraaxialmetastasisoriginatingfromaprimaryovariandysgerminoma |
_version_ |
1725965570985164800 |